BioCryst to Present at Upcoming Investor Conferences
May 05 2021 - 7:00AM
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that
the company will present at the Bank of America 2021 Healthcare
Conference on Wednesday, May 12, 2021 at 12:30 p.m. ET and the 2021
RBC Capital Markets Global Healthcare Conference on Wednesday, May
19, 2021 at 1:20 p.m. ET. Both are being conducted as virtual
conferences.
Links to a live audio webcast and replay of
these presentations may be accessed in the Investors section of
BioCryst’s website at http://www.biocryst.com.
About BioCryst
Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral,
small-molecule medicines that treat rare diseases in which
significant unmet medical needs exist and an enzyme plays a key
role in the biological pathway of the disease. Oral, once-daily
ORLADEYO™ (berotralstat) is approved in the United States, European
Union, and Japan for the prevention of HAE attacks in
adults and pediatric patients 12 years and older, and under
regulatory review for approval in the United Kingdom. BioCryst has
several ongoing development programs including BCX9930, an oral
Factor D inhibitor for the treatment of complement-mediated
diseases, BCX9250, an ALK-2 inhibitor for the treatment of
fibrodysplasia ossificans progressiva, and galidesivir, a potential
treatment for Marburg virus disease and Yellow Fever.
RAPIVAB® (peramivir injection), a viral neuraminidase
inhibitor for the treatment of influenza, has received regulatory
approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.
Post-marketing commitments for RAPIVAB are ongoing. For more
information, please visit the company’s website at
www.biocryst.com.
BCRXW
Investors:John Bluth+1 919 859
7910jbluth@biocryst.com
Media:Catherine Collier
Kyroulis+1 917 886 5586ckyroulis@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Apr 2023 to Apr 2024